- SC Injectable Vyvgart Hytrulo Gets FDA Nod for Generalized Myasthenia Gravis Monthly Prescribing Reference
- FDA Approves Subcutaneous Efgartigimod as Treatment for Generalized Myasthenia Gravis Neurology Live
- Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis Yahoo Finance
- argenx Announces U.S. Food and Drug Administration Approval GlobeNewswire
- Argenx’s Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis Benzinga
- View Full Coverage on Google News
Source link